121 related articles for article (PubMed ID: 35777027)
61. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32579175
[TBL] [Abstract][Full Text] [Related]
62. SEMA3F Promotes Liver Hepatocellular Carcinoma Metastasis by Activating Focal Adhesion Pathway.
Ye K; Ouyang X; Wang Z; Yao L; Zhang G
DNA Cell Biol; 2020 Mar; 39(3):474-483. PubMed ID: 31968181
[TBL] [Abstract][Full Text] [Related]
63. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
64. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
65. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
Guo ZY; Zhu ZT
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
[TBL] [Abstract][Full Text] [Related]
66. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
67. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
68. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma.
Shi Q; Xue C; Yuan X; He Y; Yu Z
Sci Rep; 2020 Sep; 10(1):15083. PubMed ID: 32934298
[TBL] [Abstract][Full Text] [Related]
69. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.
Gabbia D; De Martin S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834851
[TBL] [Abstract][Full Text] [Related]
70. A prognosis-related based method for miRNA selection on liver hepatocellular carcinoma prediction.
Liang G; Wu J; Xu L
Comput Biol Chem; 2021 Apr; 91():107433. PubMed ID: 33540232
[TBL] [Abstract][Full Text] [Related]
71. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
72. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
73. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
[TBL] [Abstract][Full Text] [Related]
74. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
Wang M; Xiong Z
Int J Gen Med; 2021; 14():6343-6358. PubMed ID: 34629898
[TBL] [Abstract][Full Text] [Related]
75. miR-381 Reverses Multidrug Resistance by Negative Regulation of the
Pu B; Yu X; Cao Y; Li Y; Tang L; Xia J
DNA Cell Biol; 2021 Dec; 40(12):1584-1596. PubMed ID: 34931867
[TBL] [Abstract][Full Text] [Related]
76. Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.
Yin X; Chen H; Chen S; Zhang S
Dis Markers; 2022; 2022():3736104. PubMed ID: 35401884
[TBL] [Abstract][Full Text] [Related]
77. GIV is a promising novel poor prognostic factor in liver hepatocellular carcinoma.
Zou Z; Sun Y; Wang L; Ma S; Sun C; Zhou Y; Yang G
Medicine (Baltimore); 2022 Aug; 101(32):e29645. PubMed ID: 35960100
[TBL] [Abstract][Full Text] [Related]
78. Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
Yu Y; Xie Z; Zhao M; Lian X
BMC Cancer; 2021 Apr; 21(1):368. PubMed ID: 33827485
[TBL] [Abstract][Full Text] [Related]
79. BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
Mei J; Wang R; Xia D; Yang X; Zhou W; Wang H; Liu C
DNA Cell Biol; 2020 Oct; 39(10):1838-1849. PubMed ID: 32876480
[TBL] [Abstract][Full Text] [Related]
80. Pan-cancer analysis identifies
Chang QH; Mao T; Tao Y; Dong T; Tang XX; Ge GH; Xu ZJ
Aging (Albany NY); 2021 Mar; 13(8):11096-11119. PubMed ID: 33744857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
